UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                               ------------------

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

        Date of report (Date of earliest event reported): August 16, 2005

                              --------------------

                              PharmaFrontiers Corp.
                              ---------------------
             (Exact Name of Registrant as Specified in Its Charter)


                                      Texas
                                      -----
                 (State or Other Jurisdiction of Incorporation)

            000-25513                                 76-0333165
            ---------                                 ----------
     (Commission File Number)               (I.R.S. Employer Identification No.)

 2408 Timberloch Place, Suite B-7
      The Woodlands, Texas                              77380
      --------------------                              -----
(Address of Principal Executive Offices)              (Zip Code)


       Registrant's telephone number, including area code: (281) 272-9331

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

 [ ] Written communications pursuant to Rule 425 under the Securities Act
     (17 CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act
     (17 CFR 240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))






Item 8.01. Other Events.

On August 15, 2005, Registrant filed its Quarterly Report on Form 10-QSB for the
quarter ended June 30, 2005. On August 16, 2005, Registrant announced its
results of operations in a press release. A copy of the press release is
attached as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits

(c) Exhibit 99.1

The following exhibit is to be filed as part of this 8-K:

Exhibit No.          Description
-----------          -----------
99.1                 Press release issued August 16, 2005




                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.



                                    PHARMAFRONTIERS CORP.


                                    By:  /s/ David B. McWilliams
                                    ----------------------------
                                    David B. McWilliams, Chief Executive Officer

DATE:  August 16, 2005